Advancing Ovarian Cancer Research: Model Complexity And Heterogeneity
Received Date: Aug 01, 2025 / Published Date: Aug 29, 2025
Abstract
Advancing ovarian cancer research necessitates robust preclinical models that accurately reflect tumor biology, drug efficacy, and resistance mechanisms. Current trends emphasize developing more physiologically relevant systems, including patient-derived xenografts (PDXs), genetically engineered mouse models (GEMMs), and 3D cultures like organoids and spheroids. These models enhance the study of tumor heterogeneity and the tumor microenvironment. Patient-derived organoids (PDOs) enable personalized drug sensitivity testing, while immunocompetent models are critical for evaluating immunotherapies. Single-cell technologies offer high-resolution insights into cellular dynamics and resistance. Addressing ovarian cancer’s heterogeneity through advanced preclinical models is key to developing effective treatments.
Citation: Nguyen DO (2025) Advancing Ovarian Cancer Research: Model Complexity And Heterogeneity. Current Trends Gynecol Oncol 10: 289.
Copyright: 漏 2025 Dr. Oscar Nguyen This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 168
- [From(publication date): 0-0 - Apr 07, 2026]
- Breakdown by view type
- HTML page views: 123
- PDF downloads: 45
